P2Y purinergic receptor (P2Y receptor)

P2Y purinergic receptors are a family of G protein-coupled receptors (GPCRs) that respond to extracellular nucleotides such as ATP, ADP, UTP, and UDP[1][3][5][7][8]. They are widely expressed in many tissues, notably in the vasculature, immune cells, neurons, and epithelial tissues. The P2Y receptor family includes several subtypes (e.g., P2Y₁, P2Y₂, P2Y₄, P2Y₆, P2Y₁₁, P2Y₁₂, P2Y₁₃, P2Y₁₄), each with distinct ligand specificities and functional roles[5][6][7]. They mediate diverse physiological responses, including platelet aggregation, regulation of chloride ion secretion (notably in airways), immune cell signaling, modulation of vascular tone, and neural signaling[5][6]. P2Y receptors are important therapeutic targets in conditions such as thrombosis, asthma, cystic fibrosis, inflammatory diseases, and neurodegeneration, with several drugs either in clinical use or advanced development targeting specific subtypes[6][8]. The structure of these receptors includes seven transmembrane helices typical of class A GPCRs[1], with unique diversity in their extracellular loops that determine ligand specificity. Selective pharmacological targeting has been challenging due to subtype similarity and lack of highly specific drugs for all subtypes[7]. All data points are based on synthesis from multiple authoritative sources[1][3][5][6][7][8]. If you require specific details on individual subtypes (e.g., P2Y₁ or P2Y₁₂), those can be expanded further.

Other names

P2Y receptorP2Y nucleotide receptorPurinergic P2Y receptorP2Y metabotropic receptor

Agonists stimulate receptor-mediated signal transduction, leading to effects such as chloride secretion, mucus hydration, or platelet aggregation inhibition; Antagonists block receptor, inhibiting downstream signaling (e.g., antithrombotic effect by inhibiting platelet aggregation for P2Y₁ and P2Y₁₂)